Solitary Plasmacytoma of Bone
Overview & Spectrum
Solitary plasmacytoma is a rare neoplasm defined by a single, localized mass of clonal (monoclonal) plasma cells with no evidence of systemic disease. It belongs to the plasma-cell neoplasm spectrum, the great majority of which (~95%) present as multiple myeloma.
Bone and extramedullary forms. In bone the lesion is a solitary bone plasmacytoma (SBP); in soft tissue or other extraosseous sites, commonly the head and neck, it is a solitary extramedullary plasmacytoma (SEP). SBP is the more common of the two and has the poorer prognosis, because of its higher rate of progression to multiple myeloma, even though both respond well to treatment.
Where it sits. Plasma-cell neoplasms form a continuum from MGUS (a tiny clone, no organ damage) through smouldering myeloma to multiple myeloma (systemic, with CRAB or myeloma-defining biomarkers). Solitary plasmacytoma sits apart as a localized clone, yet the bone form behaves as an early or limited-stage myeloma in many patients. The defining clinical question is therefore whether the disease is really still localized.
Pathophysiology & Epidemiology
The clone. A solitary plasmacytoma is a localized expansion of a single clone of plasma cells, the terminally differentiated B cells that normally secrete antibody. The clone usually produces a monoclonal immunoglobulin or light chain (the paraprotein, or M-protein), which is why a small serum or urine paraprotein is often detectable even when the disease looks confined to one bone.
Bone destruction. The cells home to the bone marrow microenvironment, and the same osteoimmunological machinery that drives myeloma bone disease operates locally. Plasma-cell-derived and stromal signals raise RANKL relative to OPG, along with other osteoclast-activating factors, so osteoclasts resorb bone faster than osteoblasts can repair it. The result is the characteristic lytic ('punched-out') lesion and the risk of pathological fracture.
Who gets it. Well under ~500 cases a year arise in a country the size of the USA. It tends to present a little younger than multiple myeloma, with a median age around the early 60s, and is commoner in men.
What the biopsy shows, and what it cannot. Sheets of clonal plasma cells make the diagnosis of a plasma-cell neoplasm. They cannot, by themselves, distinguish solitary plasmacytoma from multiple myeloma, which is why staging is essential.
Proving clonality is what turns "plasma cells" into a neoplastic diagnosis. Plasma cells are CD138 (syndecan-1) positive on immunohistochemistry, and clonality is shown by light-chain restriction: the population expresses either kappa or lambda, not the normal polyclonal mix (assessed by immunohistochemistry, in-situ hybridisation or flow cytometry). The clone is typically CD19-negative and CD56-positive, distinguishing it from normal plasma cells.
Presentation
Clinical features. The patient presents with bone pain at the lesion, often in the spine, also the pelvis or proximal long bones, or with its structural consequences:
- Pathological fracture or vertebral collapse
- Spinal cord or nerve-root compression from a vertebral lesion
The radiograph. A solitary lytic ('punched-out') lesion, often well-defined, is the radiographic hallmark. It is non-specific, so whole-body imaging and marrow assessment are still required to prove the disease is truly solitary before treatment.
A plasmacytoma can be osteosclerotic rather than lytic, and that variant carries a named association. An osteosclerotic plasmacytoma (single or multiple sclerotic bony lesions) is the bone lesion of POEMS syndrome: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein (characteristically a lambda light chain) and Skin changes, typically with a raised VEGF.
The dominant clinical feature is a chronic progressive demyelinating peripheral neuropathy. A sclerotic bone lesion with a small lambda paraprotein and a neuropathy should prompt the POEMS work-up, screening for the neuropathy and VEGF, rather than a "simple lytic plasmacytoma" label. Directing radiotherapy at a solitary osteosclerotic lesion can improve the polyneuropathy, so recognising the variant changes both the diagnosis and what the treatment is expected to achieve.
Investigations & Diagnostic Workup
Diagnostic criteria. A solitary bone plasmacytoma requires all of:
- A single lesion of biopsy-proven clonal plasma cells
- A bone marrow aspirate and trephine showing no clonal plasma cells
- No other lesions on whole-body imaging (MRI/PET)
- No myeloma-related end-organ damage, that is no CRAB: hyperCalcaemia, Renal impairment, Anaemia, other Bone lesions
The marrow threshold. The number that matters is 10%. Clonal marrow plasma cells of 10% or more move the diagnosis to multiple myeloma. An otherwise solitary lesion with a detectable clonal marrow population below 10% is solitary plasmacytoma with minimal marrow involvement, a distinct IMWG entity rather than a solitary plasmacytoma.
Why minimal involvement matters. It is treated the same way, with definitive radiotherapy, but carries a substantially higher risk of progression to myeloma. Separating it from truly marrow-negative disease is the reason sensitive techniques such as flow cytometry are worth using rather than morphology alone.
Clonal marrow plasma cells of 10% or more, additional lesions, or CRAB features mean the disease is systemic: it is multiple myeloma. Mislabelling multiple myeloma as solitary plasmacytoma undertreats the patient.
The work-up. Each test either confirms the diagnosis or looks for the systemic disease that would overturn it. Local MRI maps the intraosseous and soft-tissue extent and any cord involvement, and screens the marrow.
- Purpose
- Confirm clonal plasma cells (the diagnosis)
- Purpose
- Detect and quantify a paraprotein (M-protein)
- Purpose
- Sensitive clonality marker; prognostic if persistent
- Purpose
- Exclude systemic marrow clonal plasma cells
- Purpose
- Screen for CRAB (anaemia, hypercalcaemia, renal impairment)
- Purpose
- Confirm the lesion is truly solitary (more sensitive than skeletal survey)
Differential diagnosis. A solitary lytic lesion in an adult is non-specific, so a structured differential comes before the word "plasmacytoma":
- Metastasis: the commonest lytic lesion over ~40 (lung, breast, kidney, thyroid); always consider a primary elsewhere
- Multiple myeloma: the key plasma-cell mimic, and the reason the whole work-up above exists
- Lymphoma of bone, and in the right setting a leukaemic deposit
- Primary bone tumour: giant cell tumour (epiphyseal, after physeal closure), and the aggressive primaries (osteosarcoma, Ewing sarcoma, chondrosarcoma) depending on age and site
- Infection: subacute osteomyelitis or Brodie's abscess can mimic a lytic lesion
The decisive step is the same in every case: biopsy for tissue diagnosis plus staging to establish whether the lesion is solitary or part of systemic disease.
Management
Radiotherapy is the treatment of choice. Definitive radiotherapy to the lesion is the standard treatment. It gives durable long-term local control in solitary bone plasmacytoma, around 90% in modern series, and is potentially curative in the extramedullary form, which has a lower tendency to disseminate. Typical doses are in the region of 40-50 Gy, with volumes and dose/fractionation following specialist (ILROG) guidance.
Stage before you irradiate. Always complete whole-body imaging first, to be certain the disease is truly solitary before committing to localized radiotherapy.
Surgery is for structure. Surgery is not the primary treatment of the tumour itself, and operating in place of radiotherapy undertreats it. It is reserved for mechanical or neurological indications, usually combined with radiotherapy to the lesion:
- Impending or actual pathological fracture, for fixation
- Spinal instability, for stabilisation
- Cord or nerve-root compression, for decompression
Build for a survivor. When surgery is indicated, the orthopaedic principle differs from a routine metastasis. Plasmacytoma is radiosensitive and patients are often long-term survivors (5-year OS ~78%), so the reconstruction must be durable, not just palliative:
- Stable internal fixation for a fixable fracture
- Endoprosthetic or segmental replacement where bone destruction is too extensive to fix
- In the spine, decompression with instrumented stabilisation, with or without cement augmentation or vertebroplasty for a contained vertebral lesion
Sequencing surgery and radiotherapy. Radiotherapy is generally given after the surgical wound has healed, around 2-3 weeks postoperatively, to avoid wound-healing complications. For acute cord compression the priority is urgent decompression and stabilisation first, then radiotherapy to the lesion. Surgery never replaces the radiotherapy; the tumour is still irradiated.
Diagnosis before fixation. If the lesion is undiagnosed, obtain tissue and stage before definitive fixation. Fixing an unbiopsied lesion as if it were a simple fracture is the classic error.
Systemic therapy. Routine adjuvant chemotherapy is not standard for true solitary disease and its role remains debated; the evidence is limited and largely pre-novel-agent. Systemic therapy belongs to multiple myeloma, so if the work-up reclassifies the disease as systemic, the patient moves onto a myeloma regimen rather than localized radiotherapy alone.
Complications & Prognosis
Progression to myeloma. This is the dominant long-term risk. Most patients with a solitary bone plasmacytoma will eventually progress to multiple myeloma, substantially more often than with the extramedullary form, sometimes years later: around half within 5 years in bone disease, ~56% in Reed 2011. The predictors of progression:
- Bone rather than extramedullary site
- A serum paraprotein at diagnosis
- Persistence of the paraprotein after radiotherapy, the key warning sign
Treatment does not end at radiotherapy. Patients need long-term haematological follow-up, at least yearly: serial paraprotein and serum free light chains, blood counts, calcium and renal function, and imaging as indicated. Reassurance that they are "cured" after radiotherapy is unsafe.
Local and treatment-related complications. Fracture, vertebral collapse and cord or nerve-root compression are the orthopaedic burden of the lesion itself. Local failure after definitive radiotherapy is uncommon. Treatment brings its own risks: radiotherapy field effects and, when fixation or decompression is needed, surgical and anaesthetic risk.
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“A 55-year-old man has a painful solitary lytic lesion in a vertebra; biopsy shows clonal plasma cells. How do you confirm the diagnosis of solitary plasmacytoma, and why does it matter?”
“How would you treat a confirmed solitary bone plasmacytoma, when is surgery indicated, and what do you tell the patient about prognosis?”
Definition
- Single localized clonal plasma-cell tumour, no systemic disease
- Solitary bone (SBP) vs solitary extramedullary (SEP); SBP commoner, worse prognosis
- Part of the plasma-cell neoplasm spectrum (~95% present as MM)
Diagnosis
- Single biopsy-proven clonal lesion + normal marrow + no other lesions + no CRAB
- Workup: SPEP/UPEP + free light chains, FBC/Ca/renal, marrow biopsy, whole-body MRI/PET
- Whole-body MRI/PET more sensitive than skeletal survey
Management
- Radiotherapy = treatment of choice (durable local control; SEP potentially curative)
- Surgery only for fracture/instability/cord compression (+ RT)
- Chemotherapy role debated; not routine for true solitary disease
Prognosis
- High progression to multiple myeloma (more with SBP than SEP)
- Persistent paraprotein after RT predicts progression
- Needs long-term haematological surveillance
Evidence & Key Studies
Solitary plasmacytoma
- Solitary plasmacytoma is a localized clonal plasma-cell proliferation without systemic disease; solitary bone plasmacytoma is more common than the extramedullary form.
- Solitary bone plasmacytoma has poorer overall and progression-free survival than extramedullary disease because of its higher rate of evolution to multiple myeloma.
- Flow cytometry and MRI/18F-FDG PET refine diagnosis and exclude occult myeloma; radiotherapy is the treatment of choice, with the roles of surgery and chemotherapy still debated.
Solitary plasmacytoma: a review of diagnosis and management
- Both solitary bone and solitary extramedullary plasmacytoma are defined by a single localized process WITHOUT significant plasma-cell infiltration of the marrow and without end-organ damage.
- States explicitly that it is clinically important to classify plasmacytoma as having completely undetectable marrow involvement versus MINIMAL marrow involvement - these are not the same entity.
- Recent progress has been in diagnostics rather than treatment: better tools now risk-stratify disease and separate solitary plasmacytoma from quiescent or asymptomatic myeloma at diagnosis.
- Despite trials of systemic or combined-modality therapy, radiotherapy remains the mainstay.
Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group
- Definitive radiotherapy is the standard treatment for localized plasmacytoma; it provides long-term local control in solitary bone plasmacytomas and is potentially curative in extramedullary cases.
- Provides standardized work-up, target-volume and dose/fractionation recommendations for solitary plasmacytoma.
- Outlines the supportive (palliative) role of radiotherapy in multiple myeloma in the era of novel systemic agents.
The SBP-versus-SEP distinction and diagnostic refinements come from the Grammatico review (Grammatico et al., DOI), the role of radiotherapy from the ILROG guideline (Tsang et al., DOI), the myeloma-defining criteria used to exclude systemic disease from the IMWG consensus (Rajkumar et al., DOI), and the local-control and progression figures from the MD Anderson series (Reed et al., DOI). The diagnostic criteria (single lesion, normal marrow, no other lesions, no CRAB) follow standard plasma-cell-neoplasm definitions. (See also our Multiple Myeloma and Enneking Staging topics.)